BDEB76B7-B7E0-4058-82A2-77E93748C936
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 78.21944809461235
- age_years
- 61
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.516
- G2M_CHECKPOINT+0.497
- MITOTIC_SPINDLE+0.474
- MYC_TARGETS_V2+0.470
- NOTCH_SIGNALING+0.470
- WNT_BETA_CATENIN_SIGNALING+0.445
- UNFOLDED_PROTEIN_RESPONSE+0.418
- MYC_TARGETS_V1+0.410
- PROTEIN_SECRETION+0.402
- UV_RESPONSE_DN+0.384
Top 10 suppressed
- KRAS_SIGNALING_DN-0.311
- PANCREAS_BETA_CELLS-0.208
- SPERMATOGENESIS-0.139
- MYOGENESIS-0.137
- COAGULATION-0.120
- INTERFERON_ALPHA_RESPONSE-0.063
- BILE_ACID_METABOLISM-0.061
- ALLOGRAFT_REJECTION-0.060
- APICAL_SURFACE-0.059
- INTERFERON_GAMMA_RESPONSE-0.028
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 34229BDA-4BF2-4537-A663-15896F6E269A | — | — | 0.931 |
| 2 | 66A657C4-CC7B-4154-AFAD-342E7CC87EF9 | — | — | 0.896 |
| 3 | SRR934939 | — | — | 0.895 |
| 4 | SRR934827 | — | — | 0.890 |
| 5 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.888 |
| 6 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.886 |
| 7 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.876 |
| 8 | TCGA-GD-A3OQ-01A-32R-A220-07 | — | — | 0.874 |
| 9 | MNG252 | — | — | 0.872 |
| 10 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.516 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.497 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.474 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.470 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.445 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.418 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.402 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.384 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.341 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.338 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.299 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.297 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.285 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.264 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.254 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.244 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.208 | Remibrutinib | — uncovered |